TFA Therapeutics, Inc. Officially Completes Corporate Name Change. Entering a New Era of Innovative Drug Development
TFA Therapeutics, Inc. Officially Completes Corporate Name Change Entering a New Era of Innovative Drug Development July 23, 2026…
Media Report
C.S. Group Achieves Major Breakthrough in Veterinary Drug Development; Completes Phase I Clinical Trials of Antcin-Based Novel Drug, Aiming for Taiwan’s First Regulatory Approval.
C.S. Group, Taiwan’s largest specialized Taiwanofungus Camphoratus retail chain, hosted the ‘Antcin A Veterinary Drug Phase I Trials &…
A Breakthrough in Taiwanofungus Camphoratus: Applying Fungal Research to Pet Wellness.
Professional Collaboration and Quality Assurance: Partnering with veterinary networks to provide science-based wellness recommendations. We have established rigorous quality…
From the ‘Ruby of the Forest’ to Scientific Testing Standards: C.S. Group Redefines the Industrial Value of Taiwanofungus Camphoratus.
C.S. Group is redefining the Taiwanofungus Camphoratus landscape by transitioning the species from a traditional supplement to a…
C.S. Group stated that experiments combining high-purity Antcin A with steroids have confirmed a potential synergistic effect.
Dalan Huang, President of C.S. Group, emphasized that superior raw materials are the prerequisite for high-quality finished products. This…
C.S. Group: Targeting the Global Veterinary Pharmaceutical Market with Pioneering Taiwanofungus Camphoratus -Derived Novel Drugs.
The efficacy of Antcin A has long been recognized within the industry. However, the extraction process requires a massive…
C.S. Group Becomes the First Taiwan-Based Taiwanofungus Camphoratus Firm to Accomplish an OTCQB Uplisting.
C.S. Group, a pioneering enterprise listed in the U.S. capital market that specializes in restoring the rare fungal species…